Toll Free: 1-888-928-9744
Published: Feb, 2016 | Pages:
37 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Delenex Therapeutics AG - Product Pipeline Review - 2016 Summary Global Markets Direct's, 'Delenex Therapeutics AG - Product Pipeline Review - 2016', provides an overview of the Delenex Therapeutics AG's pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Delenex Therapeutics AG, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the pipeline therapeutic landscape of Delenex Therapeutics AG - The report provides overview of Delenex Therapeutics AG including its business description, key facts, and locations and subsidiaries - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report assesses Delenex Therapeutics AG's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report features Delenex Therapeutics AG's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects Reasons to Buy - Evaluate Delenex Therapeutics AG's strategic position with total access to detailed information on its product pipeline - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Delenex Therapeutics AG - Identify potential new clients or partners in the target demographic - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Delenex Therapeutics AG's pipeline depth and focus of pipeline therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Delenex Therapeutics AG Snapshot 5 Delenex Therapeutics AG Overview 5 Key Information 5 Key Facts 5 Delenex Therapeutics AG - Research and Development Overview 6 Key Therapeutic Areas 6 Delenex Therapeutics AG - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Delenex Therapeutics AG - Pipeline Products Glance 11 Delenex Therapeutics AG - Late Stage Pipeline Products 11 Phase III Products/Combination Treatment Modalities 11 Delenex Therapeutics AG - Clinical Stage Pipeline Products 12 Phase II Products/Combination Treatment Modalities 12 Phase I Products/Combination Treatment Modalities 13 Delenex Therapeutics AG - Early Stage Pipeline Products 14 Preclinical Products/Combination Treatment Modalities 14 Discovery Products/Combination Treatment Modalities 15 Delenex Therapeutics AG - Drug Profiles 16 DLX-1008 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 DLX-105 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 DLX-2323 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 DLX-2681 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 DLX-2751 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 DLX-2882 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 DLX-2907 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 DLX-2909 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 DLX-2201 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 Monoclonal Antibody Conjugate for Oncology and Inflammation 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 Monoclonal Antibody for Oncology and Inflammation 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 Monoclonal Antibody to Inhibit IL-4 and IL-13 for Atopic Dermatitis 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 Delenex Therapeutics AG - Pipeline Analysis 29 Delenex Therapeutics AG - Pipeline Products by Target 29 Delenex Therapeutics AG - Pipeline Products by Route of Administration 30 Delenex Therapeutics AG - Pipeline Products by Molecule Type 31 Delenex Therapeutics AG - Pipeline Products by Mechanism of Action 32 Delenex Therapeutics AG - Recent Pipeline Updates 33 Delenex Therapeutics AG - Dormant Projects 34 Delenex Therapeutics AG - Locations And Subsidiaries 35 Head Office 35 Appendix 36 Methodology 36 Coverage 36 Secondary Research 36 Primary Research 36 Expert Panel Validation 36 Contact Us 36 Disclaimer 37
List of Tables Delenex Therapeutics AG, Key Information 5 Delenex Therapeutics AG, Key Facts 5 Delenex Therapeutics AG - Pipeline by Indication, 2016 7 Delenex Therapeutics AG - Pipeline by Stage of Development, 2016 9 Delenex Therapeutics AG - Monotherapy Products in Pipeline, 2016 10 Delenex Therapeutics AG - Phase III, 2016 11 Delenex Therapeutics AG - Phase II, 2016 12 Delenex Therapeutics AG - Phase I, 2016 13 Delenex Therapeutics AG - Preclinical, 2016 14 Delenex Therapeutics AG - Discovery, 2016 15 Delenex Therapeutics AG - Pipeline by Target, 2016 29 Delenex Therapeutics AG - Pipeline by Route of Administration, 2016 30 Delenex Therapeutics AG - Pipeline by Molecule Type, 2016 31 Delenex Therapeutics AG - Pipeline Products by Mechanism of Action, 2016 32 Delenex Therapeutics AG - Recent Pipeline Updates, 2016 33 Delenex Therapeutics AG - Dormant Developmental Projects,2016 34
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.